Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• T-cell exhaustion limits immunotherapy effectiveness, with few drugs available to reverse it.
• Chronic IL2 receptor (IL2R)-STAT5 pathway signaling is a key driver of T-cell exhaustion.
• Targeting JAK3, a downstream IL2R-intermediate, offers a potential therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of a JAK3 inhibitor (JAK3i) in reversing T-cell exhaustion and enhancing anticancer immunotherapy.
• To evaluate the impact of different dosing strategies (pulsed high-dose vs. chronic low-dose) of JAK3i on T-cell function and tumor growth.
• To explore the combination of low-dose JAK3i with vaccine-based immunotherapies.

Main Methods:

• Utilized a specific JAK3 inhibitor (PF-06651600) to target JAK3 and inhibit STAT5 phosphorylation in vitro.
• Administered pulsed high-dose and chronic low-dose JAK3i in mouse models of solid cancer.
• Assessed T-cell effector function, tumor load, and combined JAK3i with cellular and peptide vaccines.

Main Results:

• Pulsed high-dose JAK3i impaired antitumor T-cell function.
• Chronic low-dose JAK3i significantly enhanced T-cell responses and reduced tumor burden in preclinical models.
• Combination therapy with low-dose JAK3i and vaccines further decreased tumor load compared to monotherapies.

Conclusions:

• Chronic low-dose JAK3 inhibition is a promising strategy to overcome T-cell exhaustion in cancer immunotherapy.
• JAK3 is identified as a novel and effective target for combination immunotherapy approaches.
• Low-dose JAK3i combined with vaccines demonstrates superior efficacy in reducing tumor load.